title: Comparison of mid-term clinical experience with steroid-eluting active and passive fixation ventricular electrodes in children.
abstract: Although active fixation ventricular leads seem to have advantages over passive fixation leads, this study compares the follow-up results of active and passive fixation leads in children. We evaluated the implantation and follow-up data of 41 children with active (Accufix II DEC, group 1) (n = 20) or passive (Membrane E, group 2) (n = 21) fixation, steroid-eluting ventricular leads. All but one of the patients in group 1 completed the 12-month follow-up. The mean follow-up period in group 2 was 10.4 +/- 2.9 months (range 3-12 months, median 12 months). In both groups the mean pacing threshold was measured as 0.51 +/- 0.09 V versus 0.48 +/- 0.15 V (P > 0.05) at 0.5-ms pulse width, mean R wave amplitude as 9.9 +/- 2.5 mV versus 9.4 +/- 3.2 mV (P > 0.05), and mean impedance as 557 +/- 92 omega versus 664 +/- 160 omega (P < 0.05), respectively, at implantation. After the first week of pacing, mean threshold values in group 1 were significantly lower than those of group 2 (P < 0.01 and P < 0.05, respectively). During the follow-up period, lead impedance measurements did not show a significant difference between the two groups. In one patient from group 1, the lead (by unscrewing) was removed easily because of pacemaker pocket infection. No lead dislodgement or helix deformation occurred in group 1. Nevertheless, in one patient from group 2, the lead was extracted at 4-month postimplantation because of lead displacement. We conclude that the steroid-eluting active fixation lead (Accufix II DEC) have advantages of easier implantation and lower acute and chronic stimulation thresholds compared to the passive fixation lead (Membrane E). Therefore, Accufix II DEC is superior to Membrane E, and it is a better first choice in children with an implanted single chamber ventricular pacemaker.
authors.affiliation: Department of Pediatric Cardiology, Hacettepe University Medical School, Ankara, Turkey.
authors.forename: N
authors.initials: N
authors.lastname: Ceviz
authors.forename: A
authors.initials: A
authors.lastname: Celiker
authors.forename: O
authors.initials: O
authors.lastname: Küçükosmanoğlu
authors.forename: D
authors.initials: D
authors.lastname: Alehan
authors.forename: A
authors.initials: A
authors.lastname: Kiliç
authors.forename: A
authors.initials: A
authors.lastname: Uner
authors.forename: S
authors.initials: S
authors.lastname: Ozme
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D002304:Cardiac Pacing, Artificial; D002648:Child; D002675:Child, Preschool; D020099:Coated Materials, Biocompatible; D003907:Dexamethasone / Q000008:administration & dosage; D004567:Electrodes, Implanted; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006327:Heart Block / Q000628:therapy; D006801:Humans; D007223:Infant; D008297:Male; D010138:Pacemaker, Artificial; D012804:Sick Sinus Syndrome / Q000628:therapy
chemical_list: D020099:Coated Materials, Biocompatible; D005938:Glucocorticoids; D003907:Dexamethasone